Wall Street analysts will be watching closely when Amneal Pharmaceuticals, Inc. (NYSE:AMRX) reports its quarterly earnings next, which is scheduled for Thu 7 Mar (In 60 Days). Looking at the latest analyst forecasts, the current earnings-per-share (EPS) consensus estimate is sitting at $0.33 per share. In the preceding quarter, the company reportedly generated EPS of $0.28 per share of its common stock. Looking at profitability indicators, this organization has an operating margin of -27.40%, a profit margin of -23.20% and a gross margin of 39.70%.
Speaking of Wall Street analysts, a number of market experts at top investment banks have recently posted their updated ratings on shares of Amneal Pharmaceuticals, Inc. (NYSE:AMRX). Most recently, on December 14th, 2018, Morgan Stanley Downgrade a Equal-Weight rating. Before that, on October 16th, 2018, SunTrust Downgrade to Hold. RBC Capital Mkts Upgrade a Outperform rating on August 13th, 2018, Morgan Stanley Initiated an Overweight rating on July 23rd, 2018, and B. Riley FBR, Inc. Initiated a Buy rating on June 22nd, 2018.
At its current price point, combined with the fact that this company has 283.68M shares outstanding, the current market capitalization sits at 4.21B. In the last trading day, 1,717,118 shares of Amneal Pharmaceuticals, Inc. were traded, which compares to its usual volume of about 1.08M shares per day of trading.
If we compare this company’s current price to its recent pricing activity, we can see that the price has changed by $0.79 in the past five trading days, resulting in a percentage change of +7.15% and a moving average of 13.98. In the past 20 days, its price changed by -$2.83 (which is -16.02%) and the stock’s moving average was 15.16. Looking back a full 50 days, shares of AMRX changed by -$4.15 (which is -21.85%) and demonstrated a moving average of 17.32.
Staying in the same analytical area, this company’s stock has demonstrated a 9-day Stochastic %K score of 52.99%, a 14-day Stochastic %K score of 33.93% and a 20-day Stochastic %K score of 26.15%. Using a similar metric, Amneal Pharmaceuticals, Inc. (AMRX) shares showed a Stochastic %D of 35.84% over the past 9 days, a Stochastic %D score of 25.20% over the last 14 days, and a 20-day Stochastic %D of 19.41%. Meanwhile, this stock’s MACD Oscillator was 0.32 over the past 9 days, -0.26 over the past two weeks, and -0.99 in the last 20 days.
As recent trading data suggests, this company’s shares have been hovering close to the $14.84 level. Over the past 12 months, this stock has experienced a high price of $24.48 and a low of $12.80. Top market experts pay heightened attention to a stock as it is getting closer to a notable historic high price or low price.
T Rowe Price Associates Inc purchased more shares of this company during the last fiscal quarter, as we can observe in the latest corresponding filing from AmnealPharmaceuticals, Inc. (NYSE:AMRX) with the Securities and Exchange Commission (SEC). This specific major shareholder, at the end of the quarter, held 19,302,883 shares of the company’s stock following the addition of 8,232,379 to this investor’s holdings during the three-month period. This share count represents that T Rowe Price Associates Inc now held 16.79% stake in Amneal Pharmaceuticals, Inc. (AMRX)’s shares.
Just in the most recent trading day, Amneal Pharmaceuticals, Inc. (NYSE:AMRX) experienced a high price of $15.08 and low point of $13.7. At the end of the last trading session, this stock was at 14.84 per share, following a gain of $0.23, or 9.28% during the full day.